Cantor Fitzgerald Research Analysts Lower Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) - Cantor Fitzgerald lowered their FY2024 earnings per share (EPS) estimates for Taysha Gene Therapies in a research note issued on Wednesday, May 15th. Cantor Fitzgerald analyst K. Kluska now anticipates that the company will earn ($0.53) per share for the year, down from their prior forecast of ($0.42). Cantor Fitzgerald has a "Overweight" rating and a $7.00 price objective on the stock. The consensus estimate for Taysha Gene Therapies' current full-year earnings is ($0.39) per share.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its earnings results on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.11) by $0.01. The firm had revenue of $3.41 million during the quarter, compared to the consensus estimate of $3.70 million. During the same quarter in the prior year, the firm posted ($0.28) earnings per share.

Other equities research analysts also recently issued research reports about the company. Piper Sandler began coverage on Taysha Gene Therapies in a report on Tuesday, April 9th. They set an "overweight" rating and a $9.00 target price for the company. Jefferies Financial Group reaffirmed a "buy" rating and issued a $8.00 price target (up from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday. Chardan Capital increased their target price on Taysha Gene Therapies from $5.00 to $7.00 and gave the company a "buy" rating in a report on Thursday, March 21st. JMP Securities reiterated a "market outperform" rating and set a $5.00 price target on shares of Taysha Gene Therapies in a research report on Wednesday, March 20th. Finally, Canaccord Genuity Group restated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 21st. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $7.00.

Taysha Gene Therapies Stock Down 1.6 %

NASDAQ:TSHA traded down $0.05 during midday trading on Friday, reaching $3.09. 969,789 shares of the stock traded hands, compared to its average volume of 2,423,621. Taysha Gene Therapies has a 12-month low of $0.50 and a 12-month high of $3.89. The company has a debt-to-equity ratio of 0.54, a quick ratio of 4.08 and a current ratio of 4.08. The stock has a market capitalization of $577.89 million, a PE ratio of -6.41 and a beta of 0.37. The business has a 50-day moving average of $2.63 and a two-hundred day moving average of $2.12.

Hedge Funds Weigh In On Taysha Gene Therapies

Several large investors have recently bought and sold shares of TSHA. Artal Group S.A. lifted its position in shares of Taysha Gene Therapies by 0.7% during the 1st quarter. Artal Group S.A. now owns 3,687,548 shares of the company's stock worth $10,583,000 after buying an additional 24,444 shares during the last quarter. Avoro Capital Advisors LLC lifted its position in Taysha Gene Therapies by 328.2% in the first quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company's stock valued at $53,526,000 after acquiring an additional 14,294,445 shares during the last quarter. StemPoint Capital LP acquired a new position in Taysha Gene Therapies in the first quarter valued at $3,122,000. Quantum Private Wealth LLC grew its holdings in shares of Taysha Gene Therapies by 9.2% during the first quarter. Quantum Private Wealth LLC now owns 698,520 shares of the company's stock worth $2,005,000 after purchasing an additional 59,000 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its position in shares of Taysha Gene Therapies by 66.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company's stock worth $103,000 after purchasing an additional 14,286 shares in the last quarter. Hedge funds and other institutional investors own 77.70% of the company's stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.